First cancer center in Oklahoma and fourth VA medical center to offer advanced MRI-guided radiation therapy to treat cancer. DENVER, June 13, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA … Read more
A Critical Step in the Wellness Company’s Scientific Roadmap BIRMINGHAM, Ala., June 12, 2023 /PRNewswire/ — ResBiotic Nutrition Inc (ResBiotic) announced today that its latest peer-reviewed clinical trial featuring resB® Lung Support has been published in Frontiers in Nutrition. The study, titled “Clinical Trial of a Probiotic and Herbal Supplement for Lung Health,” yielded significant … Read more
SAN FRANCISCO, June 12, 2023 /PRNewswire/ — Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce that the first patient has been enrolled today for a Phase 1 clinical … Read more
PHOENIX, June 12, 2023 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that its Board of Directors has approved a share repurchase program. The program authorizes the Company to repurchase up … Read more
SIERRA results demonstrate unprecedented bone marrow transplant access and outcomes with Iomab-B BLA filing for Iomab-B expected by year end 2023 based on positive pivotal Phase 3 SIERRA results NEW YORK, June 12, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive … Read more
Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types – NSCLC, bladder and gastroesophageal cancers Observed partial response by RECIST 1.1 (~40% tumor reduction) at first post-baseline scan in a pre-treated patient having a high priority MTAP-deletion solid tumor type Clinical strategy focused on IDE397 combinations, including with AMG … Read more
SAN DIEGO, June 11, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina’s Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior Vice President and General Counsel, … Read more
CAMBRIDGE, Mass., June 9, 2023 /PRNewswire/ — Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today presented updated preliminary data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy. Initial preliminary … Read more
CHARLOTTE, N.C., June 9, 2023 /PRNewswire/ — The company announced it had finally reached a definitive agreement with a significant infrastructure company to add up to $60 million in annual revenue, the first phase of a multi-phase series of transactions. “We started this process when Russ and Bob brought me in as Chief Executive over … Read more
PHOENIX, June 9, 2023 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the company’s Board of Directors has approved a reverse stock split of its shares of common stock at … Read more